
Alligator Bioscience sells CD40 agonist antibody to Biossil
Alligator Bioscience has signed an agreement to sell all rights and assets related to the CD40 agonist antibody mitazalimab to Biossil. Alligator will receive $750,000 upfront and is eligible for up to $108 million in milestone payments, as well as royalties on future sales, capped at $250 million in total. Under… Read More











